<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848990</url>
  </required_header>
  <id_info>
    <org_study_id>Halo-117-403</org_study_id>
    <nct_id>NCT01848990</nct_id>
  </id_info>
  <brief_title>CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)</brief_title>
  <official_title>CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halozyme Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to compare the difference in glycosylated hemoglobin
      (HbA1c) from baseline to Month 6 using Hylenex recombinant preadministration in continuous
      subcutaneous insulin infusion (CSII) versus standard CSII and to evaluate the safety of
      Hylenex recombinant preadministration, including local tolerability, adverse events, and
      hypo- and hyperglycemia rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 4 study is designed to demonstrate noninferiority of pretreatment with Hylenex
      recombinant in the CSII setting to rapid-acting analog insulin alone with respect to glycemic
      control as assessed by changes in HbA1c in participants with Type 1 diabetes mellitus.

      Total duration of study treatment is 24 months. However, according to the study design, the
      primary outcome measure is to be assessed at 6 months and an interim analysis is to be
      completed at 6 months for the secondary outcome measures and adverse events. Therefore, data
      reported in this clinical trials record is for the 6-month interim analysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 6 Months in Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline, 6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of Hypoglycemia Events (HE)</measure>
    <time_frame>After Month 1 up to Month 6</time_frame>
    <description>Overall rates of hypoglycemia (defined as blood glucose ≤70 milligrams per deciliter [mg/dL] and &lt;56 mg/dL) were based on measurements after 1 month up to 6 months. A severe HE was classified as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. A nocturnal HE was classified as an event with a blood glucose of ≤70 mg/dL with start time between 2300 and 0600, inclusive. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Hyperglycemia Events</measure>
    <time_frame>After Month 1 up to Month 6</time_frame>
    <description>Overall rates of hyperglycemia (defined as blood glucose &gt;240 mg/dL and &gt;300 mg/dL) were based on measurements after 1 month up to 6 months. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose Excursions at 6 Months</measure>
    <time_frame>After Month 1 up to Month 6</time_frame>
    <description>A 4-hour postprandial glucose excursion was measured for 3 meals after 1 month up to 6 months. For each of the 3 meals, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal (for measurements taken within 15 minutes before a meal). The average of all excursions is presented. Least Squares (LS) means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Deviation of Self-Monitoring Blood Glucose Values at 6 Months</measure>
    <time_frame>After Month 1 up to Month 6</time_frame>
    <description>Standard deviation of self-monitoring blood glucose values was calculated based on measurements taken within 15 minutes before a meal, 1 month and up to 6 months after study drug administration. LS means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">456</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Commercial Hylenex Recombinant (Formulation 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Precommercial Hylenex Recombinant (Formulation 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Rapid-Acting Insulin CSII</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Commercial Hylenex® recombinant (hyaluronidase human injection)</intervention_name>
    <arm_group_label>Commercial Hylenex Recombinant (Formulation 1)</arm_group_label>
    <other_name>Formulation 1</other_name>
    <other_name>Hylenex</other_name>
    <other_name>Recombinant human hyaluronidase (rHuPH20)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Precommercial Hylenex recombinant (hyaluronidase human injection)</intervention_name>
    <arm_group_label>Precommercial Hylenex Recombinant (Formulation 2)</arm_group_label>
    <other_name>Formulation 2</other_name>
    <other_name>Hylenex</other_name>
    <other_name>rHuPH20</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin lispro</intervention_name>
    <arm_group_label>Commercial Hylenex Recombinant (Formulation 1)</arm_group_label>
    <arm_group_label>Precommercial Hylenex Recombinant (Formulation 2)</arm_group_label>
    <arm_group_label>Standard Rapid-Acting Insulin CSII</arm_group_label>
    <other_name>Humalog</other_name>
    <other_name>Lispro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <arm_group_label>Commercial Hylenex Recombinant (Formulation 1)</arm_group_label>
    <arm_group_label>Precommercial Hylenex Recombinant (Formulation 2)</arm_group_label>
    <arm_group_label>Standard Rapid-Acting Insulin CSII</arm_group_label>
    <other_name>Novolog</other_name>
    <other_name>Aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <arm_group_label>Commercial Hylenex Recombinant (Formulation 1)</arm_group_label>
    <arm_group_label>Precommercial Hylenex Recombinant (Formulation 2)</arm_group_label>
    <arm_group_label>Standard Rapid-Acting Insulin CSII</arm_group_label>
    <other_name>Apidra</other_name>
    <other_name>Glulisine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female of age 18 years or older with a history of T1DM for at least 12 months

          2. Glycosylated hemoglobin (HbA1c) 6.5% to 9.5% (inclusive) based on central laboratory
             results

          3. Fasting C-peptide &lt;0.6 nanograms per milliliter (ng/mL)

          4. Current use of an insulin pump compatible with available tubing for Hylenex
             recombinant infusion and use of an infusion set compatible with the tubing available
             or willingness to switch to an infusion set compatible with tubing available for
             infusion of Hylenex recombinant

          5. Current treatment at the time of screening with insulin &lt;300 units per day (U/day)

          6. Participants who routinely use continuous glucose monitoring (CGM) (defined as average
             CGM use 5 or more days per week over the preceding 3 months) and those who do not
             routinely used CGM are both eligible for inclusion in the study. Intermittent use of
             CGM is also acceptable but will not be a criterion use for stratified randomization.

          7. Participants should be in good general health based on medical history and physical
             examination, without medical conditions that might prevent the completion of study
             drug infusions and assessments required in this protocol.

        Exclusion Criteria:

          1. Type 2 diabetes

          2. Known or suspected allergy to any component of any of the study drugs in this study

          3. Severe proliferative retinopathy or maculopathy, and/or gastroparesis, and/or severe
             neuropathy, in particular autonomic neuropathy, of such severity as to impede the
             participant's ability to comply with protocol procedures, as judged by the
             Investigator

          4. History of transmural myocardial infarction, congestive heart failure and uncontrolled
             hypertension (diastolic blood pressure [BP] consistently &gt;100 millimeters of mercury
             [mmHg]) are exclusionary

          5. As judged by the Investigator, clinically significant active disease of the
             gastrointestinal, cardiovascular (including history of stroke, history of arrhythmia,
             or conduction delays on electrocardiogram [ECG]), hepatic, neurological, renal,
             genitourinary, pulmonary, or hematological systems of such severity as to impede the
             participant's ability to comply with protocol procedures

          6. History of any illness or disease that in the opinion of the Investigator might
             confound the results of the study or pose additional risk in administering the study
             drugs to the participant

          7. As judged by the Investigator, clinically significant findings in routine laboratory
             data at screening

          8. Use of drugs that may interfere with the interpretation of study results or are known
             to cause clinically relevant interference with hyaluronidase action, insulin action,
             glucose utilization, or recovery from hypoglycemia (including systemic pharmacologic
             corticosteroid). Use of pramlintide or a glucagon-like peptide [GLP]-1 receptor
             agonist is not exclusionary but participants using these agents will be subjected to
             stratified randomization. Use of aspirin (acetylsalicylic acid [ASA]) up to 325
             milligrams (mg)/day is not exclusionary but should be noted for analysis.

          9. Hypoglycemic unawareness of such severity as to impede the participant's ability to
             comply with protocol procedures, as judged by the Investigator.

         10. Current addiction to alcohol or substance abuse as determined by the Investigator.

         11. Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate
             contraceptive measures (adequate contraceptive measures consist of sterilization,
             intra-uterine device [IUD], oral or injectable contraceptives, and/or barrier
             methods). Abstinence alone is not considered an adequate contraceptive measure for the
             purposes of this study.

         12. Mental incapacity, unwillingness, or language barriers precluding adequate
             understanding or cooperation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Muchmore, MD</last_name>
    <role>Study Director</role>
    <affiliation>Halozyme Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.halozyme.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2013</study_first_posted>
  <results_first_submitted>October 23, 2014</results_first_submitted>
  <results_first_submitted_qc>October 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 29, 2014</results_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Sub Cutaneous Insulin Infusion</keyword>
  <keyword>Rapid Acting Analog Insulin</keyword>
  <keyword>Hylenex</keyword>
  <keyword>Halozyme</keyword>
  <keyword>Phase 4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Commercial Hylenex Recombinant (Formulation 1)</title>
          <description>Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
        </group>
        <group group_id="P2">
          <title>Precommercial Hylenex Recombinant (Formulation 2)</title>
          <description>Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 U through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
        </group>
        <group group_id="P3">
          <title>Standard Rapid-Acting Insulin CSII</title>
          <description>Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="114">One participant was randomized and withdrew consent before start of study treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Commercial Hylenex Recombinant (Formulation 1)</title>
          <description>Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 U through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
        </group>
        <group group_id="B2">
          <title>Precommercial Hylenex Recombinant (Formulation 2)</title>
          <description>Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 U through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
        </group>
        <group group_id="B3">
          <title>Standard Rapid-Acting Insulin CSII</title>
          <description>Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="227"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="113"/>
            <count group_id="B4" value="455"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.5" spread="12.90"/>
                    <measurement group_id="B2" value="45.9" spread="13.14"/>
                    <measurement group_id="B3" value="49.7" spread="14.73"/>
                    <measurement group_id="B4" value="47.6" spread="13.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 6 Months in Glycosylated Hemoglobin (HbA1c)</title>
        <time_frame>Baseline, 6 Months</time_frame>
        <population>Participants who received at least one dose of study drug and had evaluable HbA1c data.</population>
        <group_list>
          <group group_id="O1">
            <title>Hylenex Recombinant</title>
            <description>For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of Hylenex recombinant (either Formulation 1 or Formulation 2), delivered at 150 U through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
          </group>
          <group group_id="O2">
            <title>Standard Rapid-Acting Insulin CSII</title>
            <description>Participants received their regular treatment of rapid-acting insulin CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 6 Months in Glycosylated Hemoglobin (HbA1c)</title>
          <population>Participants who received at least one dose of study drug and had evaluable HbA1c data.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.521"/>
                    <measurement group_id="O2" value="-0.18" spread="0.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size calculated based on approximately 400 participants (Pt) being enrolled. No more than 10% dropout rate at 6 months allowed at least 270 Hylenex and 90 standard CSII Pt to reach primary metabolic endpoint evaluation. Assuming HbA1c standard deviation of 0.7% and population difference of 0% between treatments, Pt reaching primary efficacy endpoint would provide &gt;90% power to demonstrate HbA1c noninferiority at margin of 0.4% using confidence bound from 2-tailed 95% confidence interval.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the upper bound of the 95% CI for the treatment difference ≤0.40, it is concluded that Hylenex recombinant preadministration is noninferior to standard CSII.</non_inferiority_desc>
            <p_value>0.4516</p_value>
            <p_value_desc>Analysis performed using analysis of variance (ANOVA) with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Means Difference</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Hypoglycemia Events (HE)</title>
        <description>Overall rates of hypoglycemia (defined as blood glucose ≤70 milligrams per deciliter [mg/dL] and &lt;56 mg/dL) were based on measurements after 1 month up to 6 months. A severe HE was classified as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. A nocturnal HE was classified as an event with a blood glucose of ≤70 mg/dL with start time between 2300 and 0600, inclusive. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>After Month 1 up to Month 6</time_frame>
        <population>Participants who received at least one dose of study drug and whose average bolus insulin dose was within 15 minutes before a meal.</population>
        <group_list>
          <group group_id="O1">
            <title>Hylenex Recombinant</title>
            <description>For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of Hylenex recombinant (either Formulation 1 or Formulation 2), delivered at 150 U through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
          </group>
          <group group_id="O2">
            <title>Standard Rapid-acting Insulin CSII</title>
            <description>Participants received their regular treatment of rapid-acting insulin CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Hypoglycemia Events (HE)</title>
          <description>Overall rates of hypoglycemia (defined as blood glucose ≤70 milligrams per deciliter [mg/dL] and &lt;56 mg/dL) were based on measurements after 1 month up to 6 months. A severe HE was classified as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. A nocturnal HE was classified as an event with a blood glucose of ≤70 mg/dL with start time between 2300 and 0600, inclusive. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Participants who received at least one dose of study drug and whose average bolus insulin dose was within 15 minutes before a meal.</population>
          <units>events per participant per month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;56 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9103"/>
                    <measurement group_id="O2" value="4.1970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤70 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6219"/>
                    <measurement group_id="O2" value="14.7112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal HEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6224"/>
                    <measurement group_id="O2" value="2.0727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe HEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0055"/>
                    <measurement group_id="O2" value="0.0160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Hyperglycemia Events</title>
        <description>Overall rates of hyperglycemia (defined as blood glucose &gt;240 mg/dL and &gt;300 mg/dL) were based on measurements after 1 month up to 6 months. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>After Month 1 up to Month 6</time_frame>
        <population>Participants who received at least one dose of study drug and whose average bolus insulin dose was within 15 minutes before a meal.</population>
        <group_list>
          <group group_id="O1">
            <title>Hylenex Recombinant</title>
            <description>For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of Hylenex recombinant (either Formulation 1 or Formulation 2), delivered at 150 U through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
          </group>
          <group group_id="O2">
            <title>Standard Rapid-acting Insulin CSII</title>
            <description>Participants received their regular treatment of rapid-acting insulin CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Hyperglycemia Events</title>
          <description>Overall rates of hyperglycemia (defined as blood glucose &gt;240 mg/dL and &gt;300 mg/dL) were based on measurements after 1 month up to 6 months. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Participants who received at least one dose of study drug and whose average bolus insulin dose was within 15 minutes before a meal.</population>
          <units>events per participant per month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;240 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0422"/>
                    <measurement group_id="O2" value="18.4696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;300 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4768"/>
                    <measurement group_id="O2" value="6.8155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose Excursions at 6 Months</title>
        <description>A 4-hour postprandial glucose excursion was measured for 3 meals after 1 month up to 6 months. For each of the 3 meals, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal (for measurements taken within 15 minutes before a meal). The average of all excursions is presented. Least Squares (LS) means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect.</description>
        <time_frame>After Month 1 up to Month 6</time_frame>
        <population>Participants who received at least one dose of study drug and had evaluable mean glucose excursion data.</population>
        <group_list>
          <group group_id="O1">
            <title>Hylenex Recombinant</title>
            <description>For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of Hylenex recombinant (either Formulation 1 or Formulation 2), delivered at 150 U through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
          </group>
          <group group_id="O2">
            <title>Standard Rapid-acting Insulin CSII</title>
            <description>Participants received their regular treatment of rapid-acting insulin CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose Excursions at 6 Months</title>
          <description>A 4-hour postprandial glucose excursion was measured for 3 meals after 1 month up to 6 months. For each of the 3 meals, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal (for measurements taken within 15 minutes before a meal). The average of all excursions is presented. Least Squares (LS) means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect.</description>
          <population>Participants who received at least one dose of study drug and had evaluable mean glucose excursion data.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breakfast (n=180, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="2.77"/>
                    <measurement group_id="O2" value="20.7" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lunch (n=182, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="2.67"/>
                    <measurement group_id="O2" value="17.9" spread="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dinner (n=181, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="2.45"/>
                    <measurement group_id="O2" value="12.5" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (n=182, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="1.70"/>
                    <measurement group_id="O2" value="16.9" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standard Deviation of Self-Monitoring Blood Glucose Values at 6 Months</title>
        <description>Standard deviation of self-monitoring blood glucose values was calculated based on measurements taken within 15 minutes before a meal, 1 month and up to 6 months after study drug administration. LS means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect.</description>
        <time_frame>After Month 1 up to Month 6</time_frame>
        <population>Participants who received at least one dose of study drug and had evaluable self-monitoring blood glucose data.</population>
        <group_list>
          <group group_id="O1">
            <title>Hylenex Recombinant</title>
            <description>For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of Hylenex recombinant (either Formulation 1 or Formulation 2), delivered at 150 U through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
          </group>
          <group group_id="O2">
            <title>Standard Rapid-acting Insulin CSII</title>
            <description>Participants received their regular treatment of rapid-acting insulin CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Standard Deviation of Self-Monitoring Blood Glucose Values at 6 Months</title>
          <description>Standard deviation of self-monitoring blood glucose values was calculated based on measurements taken within 15 minutes before a meal, 1 month and up to 6 months after study drug administration. LS means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect.</description>
          <population>Participants who received at least one dose of study drug and had evaluable self-monitoring blood glucose data.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" spread="1.09"/>
                    <measurement group_id="O2" value="72.2" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Commercial Hylenex Recombinant (Formulation 1)</title>
          <description>Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 U through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
        </group>
        <group group_id="E2">
          <title>Precommercial Hylenex Recombinant (Formulation 2)</title>
          <description>Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 U through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).</description>
        </group>
        <group group_id="E3">
          <title>Standard Rapid-Acting Insulin CSII</title>
          <description>Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic floor muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hypogonadism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site bruising</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site induration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site scar</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Injury associated with device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <description>The Verbatim term for 1 participant was &quot;Dilantin allergy&quot; and the Verbatim term for the other participant was &quot;Allergic reaction to Keflex and Bactrim”.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Infusion site infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Incision cite erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Decreased vibratory sense</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Reflexes abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Breast inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pelvic floor muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Chronic spontaneous urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Ingrowing Nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Lipohypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Onychomadesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Menopause</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The Investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless written permission from the sponsor (Halozyme) is obtained.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Endocrinology Clinical Development</name_or_title>
      <organization>Halozyme Therapeutics, Inc.</organization>
      <phone>(858) 794-8889</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

